Answers are grounded in this paper and cite their sources.
// Stefan Ehrentraut 1 , Björn Schneider 2 , Stefan Nagel 1 , Claudia Pommerenke 1 , Hilmar Quentmeier 1 , Robert Geffers 3 , Maren Feist 4 , Maren Kaufmann 1 , Corinna Meyer 1 , Marshall E. Kadin 5 , Hans G. Drexler 1 , Roderick A. F. MacLeod 1 1 Leibniz Institute - DSMZ, German Collection of Microorganisms and Cell Cultures, Department of Human and Animal Cell Cultures, Braunschweig, Germany 2 University of Rostock, Institute of Pathology and Molecular Pathology, Rostock, Germany 3 HZI - Helmholtz Center for Infection Research, Genome Analytics Research Group, Braunschweig, Germany 4 University Medical Center Goettingen, Department of Haematology and Medical Oncology, Goettingen, Germany 5 Department of Dermatology and Skin Surgery, Roger Williams Medical Center, Boston University School of Medicine, Providence, RI, USA Correspondence to: Roderick A.F. MacLeod, email: rml@dsmz.de Keywords: CTCL, IL-2, IL-17F, JAK3, SOCS1 Received: February 03, 2016 Accepted: April 10, 2016 Published: April 28, 2016 ABSTRACT We propose that deregulated T-helper-cell (Th) signaling underlies evolving Th17 cytokine expression seen during progression of cutaneous T-cell lymphoma (CTCL). Accordingly, we developed a lymphoma progression model comprising cell lines established at indolent (MAC-1) and aggressive (MAC-2A) CTCL stages. We discovered activating JAK3 (V722I) mutations present at indolent disease, reinforced in aggressive disease by novel compound heterozygous SOCS1 (G78R/D105N) JAK-binding domain inactivating mutations. Though isogenic, indolent and aggressive-stage cell lines had diverged phenotypically, the latter expressing multiple Th17 related cytokines, the former a narrower profile. Importantly, indolent stage cells remained poised for Th17 cytokine expression, readily inducible by treatment with IL-2 - a cytokine which mitigates Th17 differentiation in mice. In indolent stage cells JAK3 expression was boosted by IL-2 treatment. Th17 conversion of MAC-1 cells by IL-2 was blocked by pharmacological inhibition of JAK3 or STAT5, implicating IL2RG - JAK3 – STAT5 signaling in plasticity responses. Like IL-2 treatment, SOCS1 knockdown drove indolent stage cells to mimic key aggressive stage properties, notably IL17F upregulation. Co-immunoprecipitation experiments showed that SOCS1 mutations abolished JAK3 binding, revealing a key role for SOCS1 in regulating JAK3/STAT5 signaling. Collectively, our results show how JAK/STAT pathway mutations contribute to disease progression in CTCL cells by potentiating inflammatory cytokine signaling, widening the potential therapeutic target range for this intractable entity. MAC-1/2A cells also provide a candidate human Th17 laboratory model for identifying potentally actionable CTCL markers or targets and testing their druggability in vitro .
No takes yet. Share an insight, caveat, or question.
Ehrentraut et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: